(2Z)-2-(1H-indol-3-ylmethylidene)-1-azabicyclo[2.2.2]octan-3-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (2Z)-2-(1H-indol-3-ylmethylidene)-1-azabicyclo[2.2.2]octan-3-ol
• 化学式: C₁₆H₁₈N₂O
• 分子量: 254.33
• InChiKey: FWPQRYXMFOWDPC-DHDCSXOGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  39.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• TISSUE-PRESERVING LIQUID AND TISSUE-PRESERVING METHOD
  申请人：Osaka University

  公开号：EP2878197A1

  公开（公告）日：2015-06-03

  The present invention provides a tissue preservation sol ution that has good quality for preservation of tissues, org ans and cells, and is useful in the fields of regenerative m edicine, transplantation medicine, etc. The tissue preserva tion solution of the present invention comprises a compound having a Nrf2 activating effect. Preferable compounds havin g a Nrf2 activating effect are electrophiles, and in particu lar, ebselen and tert-butylhydroquinone. A preferable basal solution of the tissue preservation solution is Hank's bala nced salt solution.

  本发明提供了一种组织保存液，它具有良好的组织、器官和细胞保存质量，可用于再生医学、移植医学等领域。本发明的组织保存液包含一种具有 Nrf2 激活作用的化合物。具有 Nrf2 激活作用的化合物最好是嗜电化合物，特别是依布硒和叔丁基对苯二酚。组织保存溶液的基质溶液最好是汉克巴尔德盐溶液。
• TISSUE PRESERVATION SOLUTION AND TISSUE PRESERVATION METHOD
  申请人：Osaka University

  公开号：EP2878197B1

  公开（公告）日：2018-12-26
• NRF2 Deficiency Influences Susceptibility to Steroid Resistance via HDAC2 Reduction
  申请人：Rahman Irfan

  公开号：US20140080795A1

  公开（公告）日：2014-03-20

  Methods for the treatment or prevention of diseases which are caused by the decreased concentrations of histone deacetylase 2 (HDAC2) in cells are described. The diseases which may be treated by the methods of the invention include chronic obstructive pulmonary disease (COPD) and asthma, including steroid resistant COPD and asthma. The invention provides methods for treating or preventing of diseases caused by the degradation of HDAC2 by providing to the subject in need of treatment or prevention a molecular compound capable of preventing the degradation of HDAC2. Such molecular compounds include Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activators. Methods are further provided for the treatment and prevention of COPD and asthma by providing to a subject in need of such treatment and prevention a nucleic acid which causes expression of HDAC2 in lung cells and/or a nucleic acid which causes expression of Nrf2 in lung cells.
• COMPOSITIONS AND METHODS FOR THE STUDY AND TREATMENT OF ACUTE KIDNEY INJURY
  申请人：The Johns Hopkins University

  公开号：US20160120158A1

  公开（公告）日：2016-05-05

  The present invention relates to the field of nephrology. More specifically, the present invention provides compositions and methods useful for the study and treatment of acute kidney injury. In one embodiment, the present invention provides a knockout animal whose genome comprises a deletion of exon 2 and exon 3 of kelch-like ECH-associated protein 1 (KEAP1) in T-cells. In another embodiment, a method for treating a subject diagnosed with AKI comprising the steps of (a) isolating T-cells from the subject; (b) activating Nrf2 expression in the isolated T-cells; and (c) administering the T-cells back to the subject.